EyePoint granted stock options to new employees, totaling 13,900 shares, as inducement awards under NASDAQ guidelines.
Quiver AI Summary
EyePoint, Inc. announced the grant of non-statutory stock options to three new employees as part of their inducement awards outside the Company’s 2023 Long-Term Incentive Plan, totaling 13,900 shares of common stock. The stock options, effective January 15, 2026, have an exercise price of $15.84 per share and are set to vest over four years. This initiative is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to entice new talent to join EyePoint. The company is focused on developing treatments for serious retinal diseases, with its lead product candidate, DURAVYU™, currently undergoing Phase 3 trials. EyePoint is headquartered in Watertown, Massachusetts, and has a history of innovation in retinal therapies.
Potential Positives
- EyePoint granted stock options to three new employees, indicating the company's growth and commitment to attracting talent.
- The company is progressing in clinical trials for its lead product candidate, DURAVYU™, with topline data expected in mid-2026.
- EyePoint has a history of innovation, with four approved drugs over three decades, which may enhance its reputation and investor confidence.
- The FDA has conditionally accepted the proprietary name for its investigational drug, DURAVYU™, which represents a step forward in the regulatory process.
Potential Negatives
- The grant of stock options as inducement awards outside of the 2023 Long-Term Incentive Plan may raise concerns about the company's compensation practices and attract scrutiny from investors.
- The need to offer inducement stock options could indicate challenges in attracting talent, which may reflect negatively on the company's employment brand and operational stability.
- The ongoing clinical trials for DURAVYU are still in progress with uncertain FDA approval timelines, creating risks regarding the company's future revenue and market position.
FAQ
What stock options did EyePoint grant to new employees?
EyePoint granted non-statutory stock options for an aggregate of 13,900 shares to three new employees as inducement awards.
What is the exercise price for the stock options?
The exercise price for the stock options is $15.84 per share, based on the closing price on January 15, 2026.
How long is the term for the stock options granted by EyePoint?
The stock options have a ten-year term and vest over four years with specific vesting milestones.
What is EyePoint, Inc. known for?
EyePoint is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases.
What is DURAVYU™?
DURAVYU™ is EyePoint's investigational treatment for retinal diseases, combining vorolanib with advanced bioerodible technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- ASSET MANAGEMENT, LP CORMORANT sold 60,000 shares for an estimated $942,240
- RAMIRO RIBEIRO (Chief Medical Officer) has made 0 purchases and 2 sales selling 45,266 shares for an estimated $758,921.
- NANCY LURKER has made 0 purchases and 3 sales selling 10,000 shares for an estimated $150,942.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EYPT Hedge Fund Activity
We have seen 68 institutional investors add shares of $EYPT stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 2,005,365 shares (+inf%) to their portfolio in Q3 2025, for an estimated $28,556,397
- ORBIMED ADVISORS LLC added 1,796,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,575,040
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,240,218 shares (-18.2%) from their portfolio in Q3 2025, for an estimated $17,660,704
- BALYASNY ASSET MANAGEMENT L.P. added 756,087 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,766,678
- ROSALIND ADVISORS, INC. added 650,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,256,000
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 611,376 shares (-9.0%) from their portfolio in Q3 2025, for an estimated $8,705,994
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 593,091 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,445,615
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EYPT Analyst Ratings
Wall Street analysts have issued reports on $EYPT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $EYPT, check out Quiver Quantitative's $EYPT forecast page.
$EYPT Price Targets
Multiple analysts have issued price targets for $EYPT recently. We have seen 3 analysts offer price targets for $EYPT in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $39.0 on 11/06/2025
- Daniil Gataulin from Chardan Capital set a target price of $27.0 on 08/07/2025
- Yi Chen from HC Wainwright & Co. set a target price of $23.0 on 08/06/2025
Full Release
WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint common stock to three new employees. The stock options were granted on January 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $15.84 per share, the closing price of EyePoint’s common stock on January 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU ™ , is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E ™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
[email protected]
/
[email protected]
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]
